Neuphoria Therapeutics (NEUP) Income from Continuing Operations (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Income from Continuing Operations of 505063.0 for Q1 2026, down 104.48% year-over-year from 11262161.0 in Q1 2025, and down 127.09% quarter-over-quarter from 1864092.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Income from Continuing Operations for 4 consecutive years, with 505063.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 104.48% year-over-year to 505063.0; the TTM figure through Mar 2026 stood at 10788052.0 (down 274.0% YoY), while the FY2025 annual figure was 6273448.0, up 141.49% from the prior year.
- Income from Continuing Operations declined to 505063.0 in Q1 2026 per NEUP's latest filing, from 1864092.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 11262161.0 in Q1 2025 and bottomed at 9906504.0 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 1581201.45 across 4 years, with a median of 2240577.0 in 2025.
- On a YoY basis, Income from Continuing Operations climbed as much as 505.38% in 2025 and fell as far as 1130.95% in 2025.
- Neuphoria Therapeutics' Income from Continuing Operations stood at 4554424.0 in 2023, then soared by 57.33% to 1943349.0 in 2024, then jumped by 195.92% to 1864092.0 in 2025, then tumbled by 127.09% to 505063.0 in 2026.
- Business Quant data shows NEUP's Income from Continuing Operations at 505063.0 in Q1 2026, 1864092.0 in Q4 2025, and 9906504.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.75 Bn | 130.90 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.96 Bn | 77.96 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 56.33 Bn | 51.19 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.56 Bn | 28.25 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 81.49 Mn |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - | -505,063.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -505,063.00 |
| Dec 31, 2025 | 1.86 Mn |
| Sep 30, 2025 | -9.91 Mn |
| Jun 30, 2025 | -2.24 Mn |
| Mar 31, 2025 | 11.26 Mn |
| Dec 31, 2024 | -1.94 Mn |
| Sep 30, 2024 | -804,787.00 |
| Jun 30, 2024 | -2.31 Mn |
| Mar 31, 2024 | -2.78 Mn |
| Dec 31, 2023 | -4.55 Mn |
| Sep 30, 2023 | -5.47 Mn |